Literature DB >> 17562793

How the rich get richer.

Mike Rossner, Ira Mellman.   

Abstract

Entities:  

Mesh:

Year:  2007        PMID: 17562793      PMCID: PMC2064355          DOI: 10.1083/jcb.200705199

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


× No keyword cloud information.
The Howard Hughes Medical Institute (HHMI) has announced that it will pay the commercial publisher Elsevier $1,500 for each article by an HHMI investigator published in an Elsevier journal (1). This payment will allow public access to the article via PubMed Central six months after the publication date.1 Two problems with this deal immediately come to mind. First, there is a clear potential for conflict of interest when a publisher stands to benefit financially by publishing papers from a particular organization. Second, and even more seriously, this action by HHMI undermines the effort to persuade commercial publishers to make their content public after a short delay, by rewarding them for not doing so. ©cartoon-bank.com. All Rights Re-served. The HHMI–Elsevier deal coincides with an impending mandate to make publications resulting from HHMI-funded research available to the public after a six-month delay (2). To fulfill this mandate, HHMI had two options: (1) take a stand against commercial publishers by prohibiting the highly productive and influential HHMI-funding recipients from publishing in journals that do not release their content after six months, or (2) capitulate to the commercial publishers and pay them to release HHMI papers after six months. Choosing the former option had the potential to force the commercial publishers to reconsider their policies or risk losing prized content. HHMI chose the latter. For many years The Rockefeller University Press and many other nonprofit publishers have released all of their content to the public after only six months, and have proven that such a policy does not reduce subscription revenues. We thus provide all authors with a free service for which HHMI will now pay Elsevier. Commercial publishers should need no financial incentive to provide this service to the scientific research community, on whom they rely for their content, their quality control, their subscribers, and for the patronage of their advertisers. Instead, Elsevier has accepted a deal that does a disservice to that community by increasing publication costs and thus further reducing the funds available for research. HHMI has rewarded Elsevier for their steadfast refusal to release their content by further enhancing their already highly profitable business model.2 Although nonprofit publishers are motivated by the dissemination of knowledge rather than the acquisition of profits, we still require considerable sums to operate. If we can afford to release our content after six months without the benefit of HHMI's largess, then surely commercial publishers can do so as well. It is unfortunate that HHMI has forfeited its substantial bargaining power in a deal that represents a setback to the mission of public access.
  2 in total

1.  A reply from Howard Hughes Medical Institute (HHMI).

Authors:  Tom Cech; Jack Dixon; Avice Meehan; Josie Briggs; Carl Rhodes
Journal:  J Cell Biol       Date:  2007-07-23       Impact factor: 10.539

2.  By the scientists, for the scientists.

Authors:  Ira Mellman
Journal:  J Cell Biol       Date:  2009-01-12       Impact factor: 10.539

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.